Cell therapy for brain tumors: The first 60 years.

Introduction

Primary brain tumors remain among the leading causes of morbidity and mortality across all age groups. 1 , 2 Rickman J. Godlee performed the first documented successful resection of a primary brain tumor in 1884. 3 Since then, many advances have been made in neurosurgical procedures, radiation therapy, chemotherapy, and the molecular understanding of distinct brain tumor entities. 4 Yet, outcomes for many brain cancers, such as glioblastoma (GBM) and diffuse midline gliomas (DMGs), remain extremely poor. 5 , 6 Furthermore, acute and long-term toxicities of current treatment modalities, which compromise quality of life, remain a major limitation. 7

To address these limitations, immunotherapy has emerged as a promising tool to specifically activate immune cells against cancer antigens. Adoptive cell therapy is a type of immunotherapy that is based on the infusion of disease-targeting allogeneic or autologous immune cells into patients. 8 The study of adoptive cell transfer dates back to 1913, when it was observed that inoculating rats with a mixture of sarcoma cells and splenocytes led to delayed tumor growth. 9 Since then, as a result of extensive laboratory and clinical testing, cell therapy has revolutionized the treatment for relapsed/refractory B cell malignancies. 10 , 11 Meaningful results have also been achieved for patients with late-stage melanoma and refractory synovial sarcoma. 12 , 13 For the past 6 decades, cellular immunotherapies have similarly been tested in the clinic for the treatment of primary brain tumors ( Figure 1 ). 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 In this article, we review the approaches that have been tested and summarize the key takeaways from published clinical studies. While one could ask, why write a review on the history of cell therapy for brain tumors, we believe that it is as important to look back as it is to look forward. As the reader will appreciate, clinical response, albeit inconsistent, has been observed since the first cell therapy studies for brain tumors were conducted, and this insight alone puts the current results of chimeric antigen receptor (CAR) T cell therapy studies for brain tumors into perspective. As Mark Twain noted, “history doesn’t repeat itself, but it often rhymes.” Figure 1 The 60-year evolution of cell therapy trials for brain tumors (A) A timeline of key clinical milestones in cellular immunotherapy for brain tumors; year of publication is shown unless the year of infusion was reported in the publication (denoted by ∗). PubMed Identifier, PMID; for the 1972 study with no PMID, see Takakura et al. 21 (B) A timeline representing the progression of clinical implementation of major cell therapy products for brain tumors (Leukos, PBMCs, BM, leukocytes, peripheral blood mononuclear cells, bone marrow; LAKs, lymphokine-activated killer cells; TILs, tumor-infiltrating lymphocytes; NKs, natural killer cells; CARTs, chimeric antigen receptor T cells). (C) Total number of patients infused with the different major cell therapy products in clinical trials for brain tumors.

Immunotherapy with leukocytes, PBMCs, and bone marrow cells

Between 1968 and 2001, more than 200 brain tumor patients were treated with leukocytes, bone marrow cells as adjuvant immunotherapy, or peripheral blood mononuclear cells (PBMCs), and the results from these studies are summarized in Table 1 and reviewed in the following text. In the 1960s, there was convincing evidence that the immune system can recognize tumor cells via the existence of tumor neoantigens. 14 Lymphoid infiltration of brain tumors had been described and proposed as a predictor of favorable prognosis. 14 While the natural antitumor immune response is weak and easily overcome, mouse experiments have shown that immunization via “pre-transplantation” of brain tumors to any part of the body could break immune tolerance, leading to the rejection of otherwise lethal intracerebral glioblastoma grafts. 14 On the other hand, administration of immunosuppressive agents such as corticosteroids was known to impair immune function and even facilitate tumor growth. 14 Finally, today it is well recognized that systemically administered immune checkpoint inhibitors can have therapeutic effects on brain metastases and biological effects against GBMs. 29 , 30 However, at the time, it was thought that antibodies cannot cross the blood-brain barrier, so an immunotherapy for the treatment of brain tumors should be cell based. 14 This knowledge was translated into the first clinical cell therapy protocol for brain tumors in 1968. 14 , 31 Table 1 Cell therapy with leukocytes, PBMCs, and bone marrow cells Year(s) Pt (#) Diagnosis Treatment Cell dose Best clinical outcomes 1969, 14 1970 31 3 2 grade 4 GBM 1 grade 2/3 OA auto cells from lymphatic fluid after antitumor immunization 6–22 × 10 9 (i.t. and SA) OG pt: complete remission with no relapse for 17 mths 1 GBM pt: transient immune reaction at primary tumor site 1972, 21 1975 32 21 recurrent tumors pediatric: MB, GBM, OPG, pinealoma, A, DIPG adult: GBM, A, EPN, OG adjuvant pediatric: allo BM cells adult: allo or auto leukos 1–9 × 10 9 (BM: i.v.; other: i.t.) significantly higher survival compared to historical controls 1977 33 17 recurrent grade 3–4 GBMs auto PBMCs 0.01–1 × 10 9 (i.t.) 1 pt: sustained regression for 17 mths 7 pts: sustained neurological improvements and prolonged survival compared to historical controls 1978 34 4 primary grade 3–4 GBMs after surgery and radiation auto PBMCs 0.001–5 × 10 9 (IT) 1 pt: transient improvement in speech and reduction in tumor burden 1 pt: transient reduction in tumor burden 1979 35 10 primary or recurrent GBM or grade 4 A after surgery, XRT, and/or chemotherapy allo tumor RNA-sensitized leukos 0.7–1.5 × 10 9 (i.v.) extended survival or delayed recurrence compared to conventional therapy 1981 36 9 primary GBM, EPM, DIPG, OG, A (after surgical resection) auto PBMCs 0.01–1 × 10 9 (i.t.) significant improved survival compared to historical controls (avg: 23 vs. 10.3 mths) 1984 37 4 recurrent GBM auto PBMCs 0.08–4 × 10 9 (i.t.) no benefit 1987 38 18 recurrent GBM auto PBMCs labeled with indium-111 2.1–6.7 × 10 9 (IT) no benefit 1987, 39 , 40 1990 41 97 recurrent grades 2–4 glioma auto PBMCs stimulated with PHA/IL-2 0.1–5 × 10 9 (i.t.) 18 pts: no recurrence for >6–33 mths incl grade 3 ( n = 8) and 5 ( n = 4) tumors 76 pts: tumor regression or stable disease for at least 2 mths 1989, 42 1991 43 31 GBMs following initial resection auto PBMCs mixed with 3 × 10 6 IU IFN-α mean 8.6 × 10 8 (i.t.) 1 pt: transient regression for 6 mths 2 pts: stable disease for 5–6 mths 1989 44 4 MM, A, GBM auto PBMCs stimulated with auto tumor cells 0.2–1.3 × 10 8 (i.v. or i.t.) 1 pt: neurological improvement 2001 45 12 refractory GBM or A auto PBMCs stimulated with OK-432 1–11.2 × 10 7 (i.t.) 2 pts: transient stable disease 2 pts: transient minor regressions Pt (#), number of patients; A, astrocytoma; DIPG, diffuse intrinsic pontine glioma; EPN, ependymoma; GBM, glioblastoma; MB, medulloblastoma; MM, metastatic meningioma; OA, oligoastrocytoma; OG, oligodendroglioma; OPG, optic glioma; XRT, radiation therapy; allo, allogeneic; auto, autologous; BM, bone marrow; IFN, interferon; IL, interleukin; leuko, leukocyte; OK-432, lyophilized Streptococcus pyogenes ; PBMCs, peripheral blood mononuclear cells; PHA, phytohemagglutinin; IT, intrathecal; i.t., intratumoral; i.v., intravenous; SA, subarachnoid; avg, average; incl, including; mths, months; pt, patient.

In this inaugural attempt to induce “allergic encephalotumoritis” in humans, three patients’ primary tumors were resected, and bilateral tumor grafts were implanted subcutaneously into the mid-thighs. The tumor graft on the right thigh was boosted with the addition of Bacillus Calmette-Guérin (BCG) injections. Fourteen to 21 days after this procedure, immunity to the tumor grafts was confirmed by performing an intradermal reaction test using cryopreserved tumor homogenate. Once the patient was considered sensitized, lymphatic fluid was harvested via catheterization of the thoracic duct. Cells from the lymphatic fluid were concentrated, and 6–22 billion cells were injected near the primary tumor site, either intratumorally or into the subarachnoid space. 14 , 31

Following this extensive protocol, one of the patients with a grade 2/3 oligoastrocytoma achieved a complete response (CR) with no relapse or progression during 17 months of follow-up. The other two patients with grade IV GBMs had progressive disease. However, in one of the patients, histological analysis of a reoperation specimen post therapy revealed the presence of a “thick lymphocyte crown” evident of a cellular immunological reaction surrounding the primary tumor. Altogether, the authors concluded that while the therapy was safe, the overall efficacy of this treatment regimen was limited. 14 , 31

Ten other published clinical trials followed between 1972 and 2001 to evaluate the use of autologous and allogeneic leukocytes, bone marrow cell transfusions, and PBMCs. 21 , 32 , 33 , 34 , 119 , 120 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 The majority of the patients had relapsed or refractory GBMs or anaplastic astrocytomas, although in 5 of the studies, several patients were treated in the upfront setting prior to relapse. 21 , 32 , 34 , 119 , 120 , 42 , 43 The most promising clinical outcomes were produced by two studies. 33 , 41 In the first study, 17 recurrent grade III astrocytoma or GBM patients who had failed upfront radiotherapy and/or chemotherapy were treated with one or more infusions of autologous PBMCs into the tumor bed. One GBM patient, who was comatose at the time of infusion, had a sustained tumor regression and returned to full independence for 17 months post immunotherapy. Seven other patients had sustained neurological improvements and prolonged survival compared to historical controls. 33 In the second study, a total of 97 patients with recurrent malignant grade II–IV gliomas were treated with autologous lymphocytes. The lymphocytes were stimulated ex vivo with phytohemagglutinin (PHA) and interleukin (IL)-2 and then infused into the tumor bed following surgical debulking. Following immunotherapy, 76 patients had a positive initial response defined as either tumor regression or stable disease (SD) for at least 2 months after treatment. Eighteen of these responding patients, including 8 grade III and 5 grade IV tumors, remained free of recurrence during follow-up (6–33 months). 41

Promising results were also observed in clinical studies of adjuvant bone marrow cell or peripheral leukocyte infusions, which were from an allogeneic source for the majority of patients. 21 , 32 Treated patients had a significantly improved survival compared to historical controls, and one GBM patient remained alive without recurrence during the 5-year follow-up period. 32 However, many patients received their cell infusion in the upfront setting alongside conventional surgery, radiation, and chemotherapy regimens, making assessment of its benefit difficult. In addition, not all studies reported clinical benefits. 37 , 38 For example, the efficacy of an intrathecal injection of autologous leukocytes was compared with/without radiotherapy in 11 patients with recurrent GBM after resection. Five patients received only leukocytes and 6 leukocytes and radiation therapy, respectively. Patients who received only leukocytes had a shorter mean survival than patients who also received radiation therapy (4 vs. 11.4 months), highlighting that unspecific leukocytes do not have sufficient antitumor activity to prevent progression. 38

In conclusion, these early clinical trials began to demonstrate that adoptive cell therapy for brain tumors is safe and beneficial in a subset of patients who failed frontline conventional therapies. However, with less than 10%, CRs in the non-adjuvant setting were uncommon. 14 , 41

Lymphokine-activated killer cell therapy

In 1981, it was first reported that PBMCs from cancer patients could be activated and rapidly expanded to large numbers in vitro by culturing them with IL-2 for a minimum of 2 days. 46 The resulting cell product was coined lymphokine-activated killer (LAK) cells and consisted of a mixture of natural killer (NK) cells, T cells, and NK T cells. LAK cells can lyse otherwise NK cell-resistant autologous tumor cells (albeit at very high effector to target ratios) but do not kill healthy cells. 47 Following encouraging preclinical and clinical findings in the setting of pulmonary and hepatic metastases, 48 , 49 the first use of LAK cells and/or IL-2 in the treatment of human brain tumors was reported in 1986, 15 , 50 and until 2008, close to 300 patients were treated with LAK cells, which represents the largest group of patients treated with cellular immunotherapy. The results from these studies are summarized in Table S1 and reviewed in the following text.

In the first study, patients with progressive malignant glioma were treated with IL-2 with or without autologous LAK cells intratumorally at the time of surgical resection. While there were no objective antitumor responses, this trial demonstrated the feasibility and safety of locoregional LAK cell infusions. Since this original report, at least 20 early-phase clinical studies were conducted to evaluate the use of LAK cells for brain tumors. 15 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 The majority of enrolled patients were GBMs and grade III astrocytomas in the relapsed/refractory setting. However, in at least 5 studies, LAK cells were administered in the upfront setting alongside or immediately following conventional surgical resection, chemotherapy, and/or radiation therapy. 53 , 57 , 65 , 66 , 74 , 77 , 78 , 80

The best clinical responses after LAK cell therapy were observed in upfront studies where the patients were treated prior to relapse and in studies where relapsed/refractory patients were treated with LAK cells in the adjuvant setting alongside chemotherapy and/or other immunotherapies. 62 , 65 , 66 , 76 In one case report, a relapsed GBM patient’s tumor continued to rapidly progress despite re-irradiation, interferon (IFN)-β, and chemotherapy with ANCU (1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2- chloroethyl)-3-nitrosourea hydrochloride). Intratumoral infusions of autologous LAK cells were then added to the treatment regimen, and after 9 courses of LAK cells, IFN-β, and ANCU, the patient achieved a CR, which was sustained (last follow-up: >9 years). 62 , 76 Promising results were also observed in a study in which 10 patients were treated intratumorally with autologous LAK cells alone, and 10 patients were treated with autologous LAK cells that were pre-incubated with a bispecific antibody prior to infusion. The bispecific antibody consisted of a CD3 monoclonal antibody (mAb) chemically conjugated to a glioma-targeting mAb. At the time of the study, the target antigen of the glioma-targeting mAb was unknown but was later identified to be neural cell adhesion molecule (NCAM, CD56). 82 All but one patient were treated after initial tumor resection and completion of radiation therapy and/or chemotherapy. One CR was observed in the group treated with LAK cells alone, and 4 CRs in the group that received bispecific antibody pre-incubated LAK cells, respectively. 65 , 66

However, LAK cells did not produce a consistent clinical benefit in any of the conducted clinical studies. 15 , 50 , 67 , 68 , 69 , 72 While the reasons for inconsistent benefit remain largely unknown, one study highlighted that use of steroids during the month before leukapheresis was associated with a poor response to LAK cell therapy. 80 Likewise, high postsurgical tumor burden was associated with a poor response. 56 Finally, an autopsy study post LAK cell therapy demonstrated necrosis and infiltrating T cells close at the site of LAK cell administration post-surgical tumor resection but not at distant tumor sites within the brain, suggesting an inability of LAK cells to destroy macroscopic, non-resected tumor sites or their inability to migrate to tumor sites. 68

In conclusion, while some studies reported favorable outcomes in a subset of patients, the overall efficacy of LAKs with IL-2 in brain tumor patients was limited. Thus, a randomized phase 2 study for brain tumor patients was never conducted, and LAK cells were eventually eclipsed by more targeted and potent cell therapy approaches.

TILs and nonspecific and antigen-specific T cells

Between 1987 and 2018, more than 250 patients have been treated with ex - vivo -expanded tumor-infiltrating lymphocytes (TILs), non-specifically expanded T cells, or antigen-specific T cells, and the results from these studies are discussed in the following text and summarized in Table 2 . In the quest to generate therapeutic cells with better antitumor activity than LAK cells, TILs were first identified in 1986. 83 TILs consist primarily of autologous cytotoxic T cells that are isolated from tumor specimens and expanded ex vivo in the presence of IL-2 prior to re-infusion. In vivo , TILs were 50–100 times more potent than LAK cells in pulmonary and hepatic metastatic tumor models. 83 An additional advantage of TILs is the presence of subpopulations of lymphocytes that can infiltrate growing tumors, being thus potentially more capable of homing to metastatic tumor sites. While TILs have been evaluated in the clinic for other cancers, 12 leading to their Food and Drug Administration (FDA) approval for melanoma in 2024, only one clinical study for brain tumors has been published. 16 , 84 TILs were successfully expanded from the tumor specimens of all 6 patients and reinfused intratumorally. At long-term follow-up, one recurrent anaplastic astrocytoma patient had a CR (45 months), and two patients (recurrent astrocytoma or GBM) had sustained partial responses (PRs) (48 and 47 months). 16 Despite these encouraging results, no follow-up trials have been conducted in the US. Two phase 1 trials to evaluate TILs for brain tumors are currently ongoing ( NCT06640582 and NCT04943913 ), but the results have yet to be published. Table 2 Cell therapy with tumor-infiltrating lymphocytes and nonspecific and antigen-specific T cells Year(s) Pt (#) Diagnosis Treatment Cell dose Best clinical outcomes 1987 22 5 primary or recurrent AO or GBM auto T cells after in vitro antitumor immunization 5 × 10 7 (i.t.) 2 pts: PR for 20 weeks and >24 mths 1996 85 15 recurrent GBM or grade 3 A auto T cells with IL-2 after antitumor + BCG immunization 0.1–9 × 10 10 (i.v.) 10 pts: SD for 3 to >40 mths 1996, 84 1999 16 6 recurrent malignant glioma auto TILs and IL-2 1 × 10 9 (i.t.) 1 pt: CR for >45 mths 2 pts: PR for >47 mths 2 pts: PR for 6 mths 1997 86 5 recurrent grade 3–4 glioma allo T cells after auto HLA sensitization and IL-2 0.1–5.15 × 10 9 (i.t.) 2 pts: no reoccurrence for >28 mths 1 pt: SD for >28 mths 1998 87 10 recurrent GBM or grade 3 A auto T cells after antitumor + GM-CSF immunization 0.009–1.5 × 10 11 (i.v.) 1 pt: no recurrence for >12 mths 1999 88 4 recurrent GBM or anaplastic A auto T cells after in vitro antitumor immunization 0.7–7.3 × 10 7 (i.t.) 3 pts: tumor regression for 1 mth, 2 mths, and >1 year 2000 89 12 grade 2 A, anaplastic glioma, GBM after surgery and XRT auto T cells after antitumor + GM-CSF immunization 0.6–5.5 × 10 10 (i.v.) 4 pts: PR for 11 to >29 mths 2 pts: SD for >20 and >27 mths 2000 90 9 recurrent GBM or grade 3 A auto T cells with IL-2 after antitumor + BCG immunization 1–9.6 × 10 10 (i.v. or IA) 2 pts: CR for >4 and 5 years 2000 91 19 recurrent GBM or grade 3 A auto T cells after antitumor + GM-CSF immunization 0.5–5 × 10 11 (i.v.) 1 pt: CR for >17 mths 7 pts: PR for 3 to >28 mths 2 pts: SD for >7 mths 2003 92 10 recurrent GBM, anaplastic A, anaplastic OA auto T cells after in vitro antitumor immunization 0.03–2.47 × 10 9 (i.v.) 1 pt: CR for 21 mths 4 pts: PR for 1–16 mths 2008 93 3 refractory anaplastic A or EPN auto T cells after antitumor immunization unknown (i.v.) 2 pts: tumor regression for 480 days and >7 years 2010 94 5 primary GBM adjuvant auto T cells 1–1.7 × 10 10 (i.v.) 3 pts: CR for 5, 12, and >14 years 2 pts: PR for 24 and 39 mths 2012 95 1 recurrent GBM auto CMV-specific CD8 + T cells followed with TMZ after 10+ days 4 × 10 7 (i.v.) tumor regression for >17 mths 2014 19 11 recurrent GBM auto CMV-specific T cells 2.5–4 × 10 7 (i.v.) 4 pts: SD for >5 mths to >4 years 2017 96 23 primary or recurrent GBM, anaplastic OG, anaplastic OA, LGG, anaplastic EPN auto lymphokine-activated T cells +/− TMZ 6.54–9.34 × 10 7 (i.v.) 10 pts (+TMZ): 3 PR, 7SD 4 pts (−TMZ): 1 PR, 3 SD 2017 97 91 primary GBM auto T cells + TMZ 0.12–1.96 × 10 10 (i.v.) significant improved PFS compared to TMZ-only ctrl group (avg: 8.1 vs. 5.4 mths) 2018 98 23 recurrent GBM auto T cells after cancer/testis antigen-expressing T helper cell immunization 0.0054–1.86 × 10 9 (i.v.) 3 pts: tumor regressions for >14, >22, and >27 mths Pt (#), number of patients; A, astrocytoma; EPN, ependymoma; GBM, glioblastoma; LGG. low-grade glioma; OA, oligoastrocytoma; OG, oligodendroglioma; XRT, radiation therapy; allo, allogeneic; auto, autologous; BCG, Bacillus Calmette-Guerin; CMV, cytomegalovirus; GM-CSF, granulocyte-macrophage colony-stimulating factor; HLA, human leukocyte antigen; IL, interleukin; TILs, tumor-infiltrating lymphocytes; TMZ, temozolomide; IA, intraarterial; i.t., intratumoral; i.v., intravenous; avg, average; CR, complete response; ctrl, control; mths, months; PFS, progression-free survival; PR, partial response; SD, stable disease.

In addition to TILs, other strategies with ex - vivo -expanded T cells have been evaluated for brain tumors in at least 16 early-phase clinical trials conducted between 1987 and 2018. 16 , 19 , 22 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 In these studies, about half of the patients have relapsed/refractory GBMs or grade III astrocytomas. 16 , 19 , 84 , 85 , 86 , 87 , 88 , 90 , 91 , 92 , 93 , 95 , 98 The other half had newly diagnosed GBMs or other malignant gliomas, and were treated concomitantly or following primary conventional therapies. 22 , 89 , 94 , 96 , 97 In two of the studies, autologous T cells were nonspecifically expanded from PBMCs using anti-CD3 and IL-2. 94 , 97 Both studies were randomized, treated newly diagnosed GBM patients, and gave multiple doses of autologous T cells intravenously. In one study, patients received T cells immediately following a standard regimen of maximum surgical resection, ANCU chemotherapy, and radiotherapy. 94 Three out of 5 patients had CRs lasting 5 to more than 14 years, and the median survival was 96.8 months longer than that of patients who only received the standard therapy regimen without T cells. 94 In the other study, patients received T cells simultaneously with standard temozolomide (TMZ) chemotherapy and radiotherapy following maximum surgical resection. 97 Median progression-free survival was significantly longer compared to patients who received TMZ and radiotherapy only (8.1 vs. 5.4 months), but there was no difference in overall survival. 97

In the remaining studies, T cells were sensitized to tumor antigens using various strategies prior to or during ex vivo expansion. 16 , 19 , 22 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 95 , 96 , 98 In 6 of these studies, patients were immunized with an intradermal injection of their own irradiated tumor cells and an adjuvant, either granulocyte-macrophage colony-stimulating factor (GM-CSF) or BCG. 85 , 87 , 89 , 90 , 91 , 93 Following vaccination, T cells isolated from draining lymph nodes near the vaccine site or from PBMCs were activated and expanded ex vivo before intravenous infusion. In total, 56 relapsed/refractory and 12 newly diagnosed brain tumor patients were treated with this strategy. For relapsed/refractory patients, clinical activity was observed in 33 out 56 patients, including CRs (3), PRs/transient tumor regressions (15), and SD (15). 85 , 87 , 90 , 91 , 93 In the study with newly diagnosed patients, 6 out 12 patients had PRs (4) or SD (2). 89 While these findings are promising, especially for patients who have exhausted primary conventional treatments, a randomized phase 2 study has not been conducted.

Unlike the earlier clinical trials with leukocyte and LAK cell-based therapies, at least one patient in every T cell-based therapy trial experienced clinical improvement following immunotherapy. 16 , 19 , 22 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 Yet, like for LAK cell-based studies, potent and lasting antitumor responses remained rare. Reasons for the limited efficacy of cell-based immunotherapy started to emerge from preclinical studies. 99 In the 1970s, investigators had discovered that the endogenous T cell response requires the presentation of antigens on major histocompatibility complex (MHC) molecules. 100 Yet, in 2005, one study demonstrated by immunohistochemical staining of 88 primary astrocytic tumors that MHC class I expression was lost in 50% of the GBMs analyzed and that loss correlated with tumor grade. 101 Further, MHC class II expression was lost in 70% of GBMs, altogether identifying MHC downregulation as a major mechanism of immune evasion. The secretion of tumor-derived suppressive factors such as transforming growth factor (TGF)-β and prostaglandin E2 was also identified as a mechanism driving the reduced effectiveness of adoptively transferred cells. 99 T cell-based therapies have experienced a renaissance with the advent of genetic engineering, which is discussed in the CAR T cell therapy section of this review.

NK cells

Since 2004, about 50 patients have been treated with NK cell-based therapies, and the results from these studies are discussed in the following text and summarized in Table S2 . Parallel to the rise of TILs and other T cell-based adoptive therapies, NK cell-based therapies emerged as a potential immunotherapeutic strategy for brain tumors. In the first NK cell clinical trial conducted for brain tumors, 9 patients received intravenous and intratumoral autologous NK cells together with IL-2 and IFN-β. 23 Three transient PRs (50% decrease) and 2 minor responses (25% decrease) were observed. In 3 of the responding patients, only the first NK cell dose induced tumor regression, suggesting outgrowth of an NK cell-resistant tumor cell population. 23 Five other NK cell therapy studies for brain tumors have been published. 23 , 102 , 103 , 104 , 105 , 106 One of these studies was the first to explore the use of genetically modified NK cells for brain tumor patients. 102 , 103 , 106 In this study, 9 patients with recurrent human epidermal growth factor receptor 2 (HER2)+ GBM were treated with repeated intratumoral infusions of irradiated off-the-shelf HER2-CAR NK-92 cells. Following treatment, 5 patients experienced temporary SD, which lasted between 7 and 37 weeks. 105 In total, transient tumor regressions were observed in 4 out of the 6 brain tumor-specific NK cell studies, but no CRs were observed. 102 , 103 , 106 NK cell therapy for brain tumors remains under active preclinical and clinical investigation, particularly since it has become feasible to readily genetically modify NK cells to enhance their antitumor activity. 107

CAR T cells

While clinical responses were observed in the aforementioned early-phase cell therapy trials with antigen-specific T cells for brain tumors, the endogenous immune response was not sufficient to mount potent and lasting antitumor responses. 16 , 19 , 22 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 The advent of T cell engineering offered a potential solution to this roadblock by not only reliably generating brain tumor-specific T cells but also generating T cells with enhanced effector function. Initial genetic engineering approaches focused on expressing CARs in T cells to generate brain tumor-specific T cells. The original CAR structure was published in 1993 and consists of an antigen recognition domain, a hinge/transmembrane domain, and a cytoplasmic signaling domain. 8 , 108 , 109 The antigen-binding domain consists of a single-chain variable fragment (scFv) derived from a mAb or a ligand specific for a tumor-associated antigen expressed on the surface of tumor cells. This enables CAR T cells to recognize tumor cells in a non-MHC-restricted manner, rendering them resistant to immune evasion tactics of tumor cells, including downregulation of MHC. 8 The drawback of this design is that only the cell surface antigen can be targeted. However, the development of so-called “peptide-centric” CARs enables targeting of peptide derived from intracellular molecules presented by MHC molecules. 110 The cytoplasmic domain of CARs consists of signaling domains for T cell activation and costimulation, and the most common domains used are derived from CD3ζ for T cell activation and CD28 and/or 41BB (CD137) for costimulation.

CAR T cells targeting CD19 or BCMA have revolutionized the care of patients with relapsed/refractory B cell malignancies or multiple myeloma over the last 15 years, and currently, there are 7 FDA-approved CAR T cell products. 10 , 11 , 111 In contrast, early-phase clinical studies evaluating CAR T cells for solid tumors and brain tumors have shown limited activity unless in the setting of low disease burden. 112 , 113 , 114 This limited efficacy is most likely multifactorial and includes (1) low level and heterogeneous antigen expression, (2) limited expansion and persistence of CAR T cells, (3) limited homing to and penetration of tumor sites, and (4) the immunosuppressive tumor microenvironment. These roadblocks have been reviewed in several recent excellent reviews. 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 Since 2006, more than 200 patients with brain tumors have been infused with CAR T cells in 17 clinical studies, and we will focus here on reviewing clinical outcomes, which are summarized in Table 3 . 17 , 18 , 20 , 24 , 25 , 26 , 27 , 28 , 112 , 112 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 Table 3 Cell therapy with CAR T cells Year(s) Pt (#) Diagnosis Target Treatment Cell dose Best clinical outcomes CD8 + CAR T cell clones 2008, 17 2015, 24 2017 128 3 recurrent GBM IL13Rα2 Costim: no; LD: no other: HyTK transgene 0.1–1 × 10 8 (i.t.) evidence of transient inflammation and targeting of IL13Rα2+ tu cells 2017, 128 2022 129 6 recurrent GBM Costim: no; LD: no other: HyTK transgene; KO GR; IL2 0.2– 2 × 10 8 (i.t.) 2 pts: transient tumor necrosis Polyclonal CAR T cells 2023, 130 2025 112 21 DMG B7-H3 Costim: 41BB T cells: CD4:CD8 ratio, 1:1 LD: no 0.1–1 × 10 7 (i.c.v.) 1 pt: transient PR (60 days) 15 pts: SD (2 to >37.5 mths) 2021 131 1 recurrent GBM Costim: 41BB T cells: CD25/CD45RA depleted; LD: no 0.4–2 × 10 7 (i.t.) tu reduction (50 days) 2025 132 4 recurrent or refractory DMG, DHG, ATRT EGFR806 Costim: 41BB T cells: CD4:CD8 ratio, 1:1 LD: no 1–2.5 × 10 7 (i.t. or i.c.v.) 1 DMG pt: SD followed by CR (2 years) to subsequent chemotherapy 2017, 133 2021 134 10 recurrent or progressive GBM EGFRvIII Costim: 41BB T cells: bulk; LD: no 1.75–5 × 10 8 (i.v.) 1 pt: sustained SD (15 mths) 4 pts: transient SD (1–2 mths) 2019 135 18 recurrent GBM Costim: CD28/41BB T cells: bulk; LD: yes other: IL2 1 × 10 7 – 6 × 10 10 (i.v.) none 2024 136 7 newly diagnosed GBM Costim: 41BB T cells: bulk; LD: no other: anti-PD1 0.47–2 × 10 8 (i.v.) none 2021 137 3 recurrent GBM EphA2 Costim: 41BB T cells: bulk; LD: yes 1 × 10 6 /kg (i.v.) 1 pt: SD 3 mths 2022, 25 2024 127 12 H3K27M-mutant DMG, spinal DMG GD2 Costim: 41BB T cells: bulk; LD: yes (pre i.v.) other: IC9 transgene 1–3 × 10 6 /kg (i.v.) 1–3 × 10 7 (i.c.v.) 1 pt: CR (>30 mths) 1 pt: >30 mths (no change in tu vol) 3 pts: transient PR (>50%) 3 pts: transient tu vol reduction 2023 138 8 recurrent or progressive GBM Costim: CD28/41BB T cells: bulk; LD: yes other: iC9 transgene 2.5 × 10 6 /kg (i.v.) 1 × 10 5 /kg (i.t.) 4 pts: PR (2–24 mths) 1 pt: SD (4 mths) 2017 18 17 progressive recurrent GBM HER2 Costim: CD28 T cells: virus specific; LD: no 0.01–1 × 10 8 /m 2 (i.v.) 1 pt: PR (9 mths) 7 pts: SD (8 weeks to 29 mths) 2021 139 3 refractory anaplastic A, metastatic EPN Costim: 41BB T cells: CD4:CD8 ratio, 1:1 LD: no 1–2.5 × 10 7 (i.t., i.c.v.) 1 pt: SD (<90 days) 2016, 20 2024 140 65 recurrent HGG IL13Rα2 Costim: 41BB T cells: TCM, TSCM LD: no 0.02–2 × 10 8 (i.t., i.c.v.; i.t./i.c.v.) 2 pts: CR (7.5 mths, >43 mths) 2 pts: PR (1 mths, 9 mths) 10 pts: SD (3–15 mths) 16 pts: SD (51–90 days) 2025 141 4 recurrent GBM CLTX Costim: CD28 T cells: TCM, TSCM LD: no 0.4–2 × 10 7 (i.t.) 3 pts: SD (1–2 mths) Polyclonal CAR T cells with genetic modification to enhance antitumor activity 2024 26 3 recurrent GBM EGFRvIII EGFR∗ Costim: 41BB T cells: bulk; LD: no other: T cell engager 1 × 10 7 (i.c.v.) 1 pt: PR lasting >5 mths 1 pt: transient PRs 2024, 27 2025 142 18 recurrent or progressive GBM EGFR IL13Rα2 Costim: 41BB T cells: bulk; LD: no other: 2 nd CAR 0.5–2.5 × 10 7 (i.c.v.) 1 pt: PR (3 mths), 2 pts: SD (>7.7 mths, >16.6 mths) 9 pts: SD (1–3 mths) 2024 28 11 H3K27M-mutant DMG, MB, ATRT GD2 Costim: 41BB T cells: bulk; LD: yes other: C7R transgene (8) (i.v.) 2 pts: PR (>1 year, <20 weeks) 5 pts: SD (<30 weeks) 3 pts: transient neurological improvement for <3 weeks Pt (#), number of patients; A, astrocytoma; ATRT, atypical teratoid/rhabdoid tumor; DHG, diffuse hemispheric glioma; DMG, diffuse midline glioma; EPN, ependymoma; GBM, glioblastoma; HGG, high-grade glioma; MB, medulloblastoma; ∗ , targeted with bispecific T cell engager ; B7-H3, CD276; EGFR806, epidermal growth factor receptor epitope defined by mAb 806 (cancer specific); EGFRvIII, EGFR variant III (cancer specific); EphA2, EPH receptor A2; GD2, disialoganglioside; HER2, human epidermal growth factor receptor 2; IL13Rα2, IL-13 receptor subunit alpha 2; CLTX, chlorotoxin; Costim, costimulatory domain of CAR; GR, glucocorticoid receptor; HyTK, hygromycin phosphotransferase gene/herpes simplex virus type 1 thymidine kinase fusion gene; iC9, inducible caspase-9 gene; KO, knockout; pre i.v., before i.v. infusion; i.c.v., intracerebroventricular; i.t., intratumoral; i.v., intravenous; CR, complete response; mths, months; PR, partial response; SD, stable disease; tu, tumor; vol, volume.

Monospecific CAR T cells targeting IL13Rα2, HER2, GD2, EGFR variants (vIII; E806), and EphA2 have been explored in early-phase clinical studies in addition to bispecific CAR T cells expressing (1) two CARs specific for IL13Rα2 and EGFR or (2) one CAR specific for EGFRvIII and one bispecific T cell engager specific for EGFR. Second genetic modifications to enhance safety (inducible caspase-9; iC9) or improve antitumor activity (constitutive active IL-7 receptor, C7R) of CAR T cells have also been explored. 25 , 28 , 127 , 138

The first brain tumor patient was treated with CAR T cells targeting IL13Rα2 in 2006. 24 In this trial, 3 recurrent/refractory grade III or IV glioma patients were treated with repeated intratumoral injections of CD8 + CAR T cell clones that expressed an IL13Rα2-CAR with a CD3ζ signaling domain. 17 , 24 , 128 While no objective antitumor responses were observed, this study illustrated that repeat CAR T cell administration to brain tumor patients was both feasible and safe. CD8 + IL13Rα2-CAR T cell clones were explored in one follow-up study in which the glucocorticoid receptor was knocked out and clones were infused with IL-2 to boost their antitumor activity. However, only transient responses were observed in 2 out of 6 patients. 129

The first major clinical successes of CAR T cells for brain tumors were observed in a large follow-up phase 1 trial. 20 , 140 In this trial, polyclonal T cells were evaluated that expressed an IL13Rα2-CAR with a 41BB.CD3ζ signaling domain to not only provide T cell activation but also provide costimulation. A total of 92 patients with recurrent high-grade glioma received IL13Rα2-CAR T cells either into the tumor cavity post resection and/or intracerebroventricularly in this trial between 2015 and 2020. Two patients achieved a CR (7.5 months; 3 years, ongoing), 2 patients achieved transient PRs, 10 patients achieved sustained SD lasting 3–15 months, 16 patients achieved transient SD lasting 51–90 days, and 62 patients had no response. 20 , 140 This trial is also the first published report of delivering cell therapy to brain tumors using intracerebroventricular (i.c.v.) injection. The trial initially opened as a two-arm study evaluating only intratumoral delivery following biopsy or resection. However, three additional arms involving i.c.v. or dual intratumoral/i.c.v. delivery were later added. The rationale to add i.c.v. dosing stemmed from early clinical experience on the trial involving a patient with recurrent, highly aggressive multifocal leptomeningeal GBM. 20 This patient initially received six weekly CAR T cell infusions into the resected cavity of the largest tumor, resulting in stabilization of the local treated site. However, during this initial treatment, the patient’s nonresected tumor continued to progress, and multiple new brain and spine lesions appeared. The patient then received 10 additional i.c.v. CAR T cell injections, resulting in what appeared to be a complete elimination of all the patient’s tumors, which persisted for 7.5 months. This clinical experience, combined with supporting preclinical data suggesting that i.c.v. delivery is more effective for trafficking cells to sites of multifocal disease, provides a strong rationale for further exploration of i.c.v. administration of CAR T cells. 20 , 143

To date, findings from 18 ongoing and completed early-phase CAR T cell clinical trials for brain tumors have been published. 17 , 18 , 20 , 24 , 25 , 26 , 27 , 28 , 112 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 142 Clinical responses have been consistently observed in clinical studies targeting HER2, GD2, and B7-H3 in subset of patients, particularly for pediatric DMG after i.c.v. or intravenous infusion of autologous GD2-CAR or B7-H3-CAR T cells. 25 , 112 , 127 , 130 This led to a 2-fold increase in median survival in comparison to historical controls (∼20 vs. 10 months). In contrast, clinical responses were only observed in 1 out of 3 clinical studies targeting EGFRvIII. 133 , 134 , 135 , 136 While these monospecific CAR T cell therapy studies overall demonstrated safety, toxicities were also observed due to local inflammatory responses at the tumor sites that included pseudoprogression. These side effects were coined tumor inflammation-associated neurotoxicity (TIAN) to contrast them from the immune effector cell-associated neurotoxicity syndrome (ICANS) observed in patients after CAR T cell therapy, who do not have brain tumors. 144

Three clinical studies have been conducted that explored a second genetic modification to improve CAR T cell function. 26 , 27 , 28 , 142 , 142 In two of the studies, different bispecific CAR T cells were infused: one expressing a 2 nd CAR (EGFR and IL13Rα2) and the other expressing a CAR (EGFRvIII) and a bispecific T cell engager that recognizes EGFR and CD3ε. 26 , 27 , 142 In the third study, GD2-CAR T cells were genetically modified to express a constitutive active IL-7 cytokine receptor (C7R). 28 The safety and efficacy of i.c.v.-delivered EGFR/IL13Rα2-CAR T cells were evaluated in 18 adult patients with GBM. 27 , 142 Early-onset neurotoxicity was consistently observed, and several patients had clinical benefit, including one PR, one sustained SD (>7.7 months), and 9 transient SD (1–3 months). 27 , 142 Three patients with GBM have been reported after the i.c.v. administration of T cells expressing EGFRvIII-CARs and EGFR T cell engagers. 26 Early-onset neurotoxicity was observed in 2 out of 3 patients, and one patient had a sustained PR (>5 months) and two transient PRs, respectively. 26 Finally, the safety and efficacy of intravenously administered GD2-CAR T cells and GD2-CAR T cells expressing C7R (GD2-CAR.C7R) T cells were compared in one study for pediatric patients with DMG. 28 Three patients received GD2-CAR T cells, and eight received GD2-CAR.C7R T cells. Patients receiving GD2-CAR.C7R T cells had improvement from baseline neurologic deficits (2 to >12 months), and PRs were observed in two patients. In contrast, in the GD2-CAR T cell patient cohort, benefits were limited. 28

Correlative analyses from clinical trials of CAR T cell therapy for brain tumors have highlighted mechanisms of immune evasion, including the development of antigen-loss variants, adaptive changes in the tumor microenvironment such as an influx of myeloid cells and inhibitory regulatory T cells, and increased expression of inhibitory molecules such as PD-L1, PD-L2, PD1, TIM3, and indoleamine 2,3-dioxygenase 1 (IDO1). 20 , 25 , 130 , 133 , 134 , 136 , 138

Discussion and outlook

Cellular therapy has been explored for brain tumors for the last six decades. Early clinical studies aimed to augment antitumor immune response with infusions of nonspecific leukocytes, PBMCs, bone marrow cells, LAK cells, and ex - vivo -activated NK- and T cells. Durable responses were rare, but CRs in a subset of patients were observed, especially when cell therapy was combined with conventional therapy or administered in the upfront setting. However, it is important to acknowledge that many of these studies were conducted using standardized response criteria, such as the McDonald Criteria, 145 which were developed prior to the widespread recognition of pseudoprogression. 146 Pseudoprogression refers to transient treatment-related effects such as enhanced tumor lesions, increased contrast enhancement, and edema that occur in around 20%–30% of brain tumor patients following chemoradiotherapy and/or immunotherapy. 146 These effects can mimic tumor growth on MRI, but unlike true tumor progression, these effects eventually subside without any change in therapy. 146 The recognition of pseudoprogression and advancements in imaging technologies led to the widespread implementation of the more rigorous Response Assessment in Neuro-Oncology Criteria for High-Grade Gliomas (RANO-HGG) recommendations, published in 2010, 147 and the updated RANO 2.0 criteria, published in 2023. 148 Enrollment of patients and interpretations of outcomes from earlier clinical studies were likely impacted by the limited recognition of pseudoprogression at the time. Thus, these earlier historical clinical outcomes should be contextualized in relation to the imaging technologies and response guidelines available at the time, and caution should be exercised when directly comparing the findings to more recent clinical trials.

The advent of genetic engineering enabled the specific targeting of antigens expressed on brain tumor cells with CAR T cells. However, despite being able to directly target brain tumor cells, the clinical activity of CAR T cells has been limited. This lack of efficacy is most likely multifactorial and includes, but is not limited to, heterogeneous expression of the targeted antigens, limited ability of immune cells to traffic to and penetrate brain tumors, and the hostile tumor microenvironment. These roadblocks have been recently discussed in detail in several excellent review articles. 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 Despite the caveats of pseudoprogression, many lessons from the earlier cell therapy trials can be applied toward overcoming the barriers to effective CAR T cell therapies. For example, the best clinical responses from the early clinical studies were observed when patients were treated in the upfront setting prior to relapse or when relapsed/refractory patients were treated with cell therapy in the adjuvant setting alongside chemotherapy and/or other immunotherapies. 62 , 65 , 66 , 76 , 94 , 97 Currently, CAR T cells are being largely evaluated in the clinic as monotherapy for the treatment of relapsed/refractory CNS disease. 17 , 18 , 20 , 24 , 25 , 26 , 27 , 28 , 112 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 Thus, moving CAR T cells into the upfront treatment setting and incorporating combinatorial approaches hold promise to improve their efficacy. In addition, steroid use during the month before leukapheresis was associated with poor responses to LAKs. 80 High doses of corticosteroids are similarly known to negatively impact CAR T cells in preclinical models, 143 , 149 yet they are currently widely used to manage CNS edema before and during CAR T cell treatment. 17 , 18 , 20 , 24 , 25 , 26 , 27 , 28 , 112 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 Thus, investigation into alternative forms of edema management is warranted to preserve CAR T cell efficacy while managing baseline and treatment-related edema.

Altogether, counteracting these roadblocks with additional genetic modification of CAR T cells and combinatorial therapies holds the promise to improve their efficacy. Likewise, other immune cell subsets, including genetically engineered NK cells, warrant further exploration. We are hopeful that over the next two decades, these refined cell therapy approaches will induce durable remissions in pediatric and adult patients diagnosed with brain tumors.

Acknowledgments

This work was supported by 10.13039/100000065 NINDS grant nos. R01NS121249 and R01NS122859 to G.K., 10.13039/100000054 NCI grant no. U01CA281823 to G.K., Alliance for Cancer Gene Therapy , Alex's Lemonade Stand Foundation (ALSF), and the American Lebanese Syrian Associated Charities to G.K. and S.G. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions

S.M. wrote the first draft of the manuscript and designed the figure. S.M., G.K., and S.G. reviewed and edited the manuscript.

Declaration of interests

G.K. and S.G. have patents or patent applications in the fields of cell or gene therapy for cancer. S.G. is a member of the Scientific Advisory Board of Be Biopharma and the Data and Safety Monitoring Board (DSMB) of Immatics.

References

1 Rouse C. Gittleman H. Ostrom Q.T. Kruchko C. Barnholtz-Sloan J.S. Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010 Neuro Oncol. 18 2016 70 77 10.1093/neuonc/nov249 26459813 PMC4677421

2 Miller K.D. Ostrom Q.T. Kruchko C. Patil N. Tihan T. Cioffi G. Fuchs H.E. Waite K.A. Jemal A. Siegel R.L. Barnholtz-Sloan J.S. Brain and other central nervous system tumor statistics, 2021 CA Cancer J. Clin. 71 2021 381 406 10.3322/caac.21693 34427324

3 Kirkpatrick D.B. The first primary brain-tumor operation J. Neurosurg. 61 1984 809 813 10.3171/jns.1984.61.5.0809 6387062

4 Pollack I.F. Agnihotri S. Broniscer A. Childhood brain tumors: current management, biological insights, and future directions J. Neurosurg. Pediatr. 23 2019 261 273 10.3171/2018.10.Peds18377 30835699 PMC6823600

5 Stupp R. Mason W.P. van den Bent M.J. Weller M. Fisher B. Taphoorn M.J.B. Belanger K. Brandes A.A. Marosi C. Bogdahn U. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996 10.1056/NEJMoa043330 15758009

6 Hoffman L.M. Veldhuijzen van Zanten S.E.M. Colditz N. Baugh J. Chaney B. Hoffmann M. Lane A. Fuller C. Miles L. Hawkins C. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries J. Clin. Oncol. 36 2018 1963 1972 10.1200/jco.2017.75.9308 29746225 PMC6075859

7 Angoumis K. Padilla C.S. Kouwenhoven M.C.M. Bijlsma R.M. Kaal S.E.J. Tromp J.M. Bos M.E.M.M. van der Hulle T. Broen M.P.G. Nuver J. Adverse health outcomes and health-related quality of life (HRQoL) among long-term adolescent and young adult (AYA) brain tumour survivors: results from the population-based SURVAYA study Support. Care Cancer 33 2025 95 10.1007/s00520-025-09155-9 39808329 PMC11732903

8 Singh A.K. McGuirk J.P. CAR T cells: continuation in a revolution of immunotherapy Lancet Oncol. 21 2020 e168 e178 10.1016/s1470-2045(19)30823-x 32135120

9 Woglom W.H. Absorption of the Protective Agent from Rats Resistant to a Transplantable Sarcoma Am. J. Cancer 17 1933 873 893 10.1158/ajc.1933.873

10 Gardner R.A. Finney O. Annesley C. Brakke H. Summers C. Leger K. Bleakley M. Brown C. Mgebroff S. Kelly-Spratt K.S. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults Blood 129 2017 3322 3331 10.1182/blood-2017-02-769208 28408462 PMC5482103

11 Maude S.L. Frey N. Shaw P.A. Aplenc R. Barrett D.M. Bunin N.J. Chew A. Gonzalez V.E. Zheng Z. Lacey S.F. Chimeric antigen receptor T cells for sustained remissions in leukemia N. Engl. J. Med. 371 2014 1507 1517 10.1056/NEJMoa1407222 25317870 PMC4267531

12 Sarnaik A.A. Hamid O. Khushalani N.I. Lewis K.D. Medina T. Kluger H.M. Thomas S.S. Domingo-Musibay E. Pavlick A.C. Whitman E.D. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma J. Clin. Oncol. 39 2021 2656 2666 10.1200/jco.21.00612 33979178 PMC8376325

13 D'Angelo S.P. Araujo D.M. Abdul Razak A.R. Agulnik M. Attia S. Blay J.Y. Carrasco Garcia I. Charlson J.A. Choy E. Demetri G.D. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial Lancet 403 2024 1460 1471 10.1016/s0140-6736(24)00319-2 38554725 PMC11419333

14 Trouillas P. Lapras C. Cellular immunotherapy of cerebral glioblastoma. Apropos of 2 results] J. Med. Lyon 50 1969 1269 1291 4320802

15 Jacobs S.K. Wilson D.J. Kornblith P.L. Grimm E.A. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial Cancer Res. 46 1986 2101 2104 3512079

16 Quattrocchi K.B. Miller C.H. Cush S. Bernard S.A. Dull S.T. Smith M. Gudeman S. Varia M.A. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas J. Neuro Oncol. 45 1999 141 157 10.1023/a:1006293606710 10778730

17 Yaghoubi S.S. Jensen M.C. Satyamurthy N. Budhiraja S. Paik D. Czernin J. Gambhir S.S. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma Nat. Clin. Pract. Oncol. 6 2009 53 58 10.1038/ncponc1278 19015650 PMC3526373

18 Ahmed N. Brawley V. Hegde M. Bielamowicz K. Kalra M. Landi D. Robertson C. Gray T.L. Diouf O. Wakefield A. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial JAMA Oncol. 3 2017 1094 1101 10.1001/jamaoncol.2017.0184 28426845 PMC5747970

19 Schuessler A. Smith C. Beagley L. Boyle G.M. Rehan S. Matthews K. Jones L. Crough T. Dasari V. Klein K. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma Cancer Res. 74 2014 3466 3476 10.1158/0008-5472.Can-14-0296 24795429

20 Brown C.E. Alizadeh D. Starr R. Weng L. Wagner J.R. Naranjo A. Ostberg J.R. Blanchard M.S. Kilpatrick J. Simpson J. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy N. Engl. J. Med. 375 2016 2561 2569 10.1056/NEJMoa1610497 28029927 PMC5390684

21 TAKAKURA K. MIKI Y. KUBO O. OGAWA N. MATSUTANI M. SANO K. Adjuvant Immunotherapy for Malignant Brain Tumors Jpn. J. Clin. Oncol. 2 1972 109 120 10.1093/oxfordjournals.jjco.a039811

22 Kitahara T. Watanabe O. Yamaura A. Makino H. Watanabe T. Suzuki G. Okumura K. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor J. Neuro Oncol. 4 1987 329 336 10.1007/bf00195603 3494820

23 Ishikawa E. Tsuboi K. Saijo K. Harada H. Takano S. Nose T. Ohno T. Autologous natural killer cell therapy for human recurrent malignant glioma Anticancer Res. 24 2004 1861 1871 15274367

24 Brown C.E. Badie B. Barish M.E. Weng L. Ostberg J.R. Chang W.C. Naranjo A. Starr R. Wagner J. Wright C. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma Clin. Cancer Res. 21 2015 4062 4072 10.1158/1078-0432.Ccr-15-0428 26059190 PMC4632968

25 Majzner R.G. Ramakrishna S. Yeom K.W. Patel S. Chinnasamy H. Schultz L.M. Richards R.M. Jiang L. Barsan V. Mancusi R. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas Nature 603 2022 934 941 10.1038/s41586-022-04489-4 35130560 PMC8967714

26 Choi B.D. Gerstner E.R. Frigault M.J. Leick M.B. Mount C.W. Balaj L. Nikiforow S. Carter B.S. Curry W.T. Gallagher K. Maus M.V. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma N. Engl. J. Med. 390 2024 1290 1298 10.1056/NEJMoa2314390 38477966 PMC11162836

27 Bagley S.J. Logun M. Fraietta J.A. Wang X. Desai A.S. Bagley L.J. Nabavizadeh A. Jarocha D. Martins R. Maloney E. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results Nat. Med. 30 2024 1320 1329 10.1038/s41591-024-02893-z 38480922 PMC13123313

28 Lin F.Y. Stuckert A. Tat C. White M. Ruggieri L. Zhang H. Mehta B. Lapteva N. Mei Z. Major A. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors J. Clin. Oncol. 42 2024 2769 2779 10.1200/jco.23.02019 38771986 PMC11305939

29 McFaline-Figueroa J.R. Sun L. Youssef G.C. Huang R. Li G. Kim J. Lee E.Q. Nayak L. Chukwueke U. Beroukhim R. Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort Nat. Commun. 15 2024 10757 10.1038/s41467-024-54326-7 PMC11685579 39737895

30 Long G.V. Shklovskaya E. Satgunaseelan L. Mao Y. da Silva I.P. Perry K.A. Diefenbach R.J. Gide T.N. Shivalingam B. Buckland M.E. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma Nat. Med. 31 2025 1557 1566 10.1038/s41591-025-03512-1 40016450 PMC12092302

31 Trouillas P. Lapras C. [Active immunotherapy of cerebral tumor. 20 cases] Neurochirurgie 16 1970 143 170 4317954

32 Takakura K. Miki Y. Kubo O. Adjuvant immunotherapy for malignant brain tumors in infants and children Childs Brain 1 1975 141 147 10.1159/000119563 1102267

33 Young H. Kaplan A. Regelson W. Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrrent glioblastoma multiforme: a preliminary report Cancer 40 1977 1037 1044 10.1002/1097-0142(197709)40:3<1037::aid-cncr2820400311>3.0.co;2-9 198084

34 Neuwelt E.A. Clark K. Kirkpatrick J.B. Toben H. Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: a toxicity study Ann. Neurol. 4 1978 307 312 10.1002/ana.410040404 581544

35 Mita R. Iwabuchi T. Treatment of malignant glioma by immunotherapy using lymphocytes sensitized with tumor-specific immune RNA (author's transl)] Neurol. Med.-Chir. 19 1979 335 341 10.2176/nmc.19.335 86971

36 Ishizawa A. [Immunotherapy for malignant gliomas (author's transl)] Neurol. Med.-Chir. 21 1981 179 191 10.2176/nmc.21.179 6164941

37 Steinbok P. Thomas J.P. Grossman L. Dolman C.L. Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme. A phase 1 (toxicity) study J. Neuro Oncol. 2 1984 147 151 10.1007/bf00177901 6090602

38 Vaquero J. Martínez R. Barbolla L. de Haro J. de Oya S. Coca S. Ramiro J. Intrathecal injection of autologous leucocytes in glioblastoma: circulatory dynamics within the subarachnoid space and clinical results Acta Neurochir. 89 1987 37 42 10.1007/bf01406665 3434340

39 Ingram M. Jacques S. Freshwater D.B. Techy G.B. Shelden C.H. Helsper J.T. Salvage immunotherapy of malignant glioma Arch. Surg. 122 1987 1483 1486 10.1001/archsurg.1987.01400240131025 3500693

40 Ingram M. Shelden C.H. Jacques S. Skillen R.G. Bradley W.G. Techy G.B. Freshwater D.B. Abts R.M. Rand R.W. Preliminary clinical trial of immunotherapy for malignant glioma J. Biol. Response Mod. 6 1987 489 498 3316510

41 Ingram M. Buckwalter J.G. Jacques D.B. Freshwater D.B. Abts R.M. Techy G.B. Miyagi K. Shelden C.H. Rand R.W. English L.W. Immunotherapy for recurrent malignant glioma: an interim report on survival Neurol. Res. 12 1990 265 273 10.1080/01616412.1990.11739955 1982172

42 Vaquero J. Martínez R. Oya S. Coca S. Barbolla L. Ramiro J. Salazar F.G. Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma Acta Neurochir. 98 1989 35 41 10.1007/bf01407174 2472737

43 Vaquero J. Martínez R. Ramiro J. Salazar F.G. Barbolla L. Regidor C. Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study Acta Neurochir. 109 1991 42 45 10.1007/bf01405696 2068965

44 Moriki A. [Induction of LAK cells and CTL in patients with brain tumor and research of its clinical application] Nihon Geka Hokan 58 1989 107 118 2802908

45 Hirotsu T. Mineta T. Ichinose M. Toda K. Fukuyama K. Tabuchi K. Adoptive immunotherapy for malignant brain tumors using human peripheral blood mononuclear cells activated by the Streptococcal preparation OK-432 Neurol. Med.-Chir. 41 2001 387 392 10.2176/nmc.41.387 11561349

46 Lotze M.T. Grimm E.A. Mazumder A. Strausser J.L. Rosenberg S.A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor Cancer Res. 41 1981 4420 4425 6975652

47 Grimm E.A. Mazumder A. Zhang H.Z. Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes J. Exp. Med. 155 1982 1823 1841 10.1084/jem.155.6.1823 6176669 PMC2186695

48 Mulé J.J. Shu S. Schwarz S.L. Rosenberg S.A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2 Science 225 1984 1487 1489 10.1126/science.6332379 6332379

49 Rosenberg S.A. Lotze M.T. Muul L.M. Leitman S. Chang A.E. Ettinghausen S.E. Matory Y.L. Skibber J.M. Shiloni E. Vetto J.T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N. Engl. J. Med. 313 1985 1485 1492 10.1056/nejm198512053132327 3903508

50 Jacobs S.K. Wilson D.J. Kornblith P.L. Grimm E.A. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report J. Neurosurg. 64 1986 743 749 10.3171/jns.1986.64.5.0743 3517250

51 Silvani A. Salmaggi A. Parmiani G. Boiardi A. Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report Neurosurgery 34 1994 1078 1081 10.1227/00006123-199406000-00021 8084395

52 Itoh K. Sawamura Y. Hosokawa M. Kobayashi H. Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor Radiat. Med. 6 1988 276 281 2854899

53 Hayes R.L. Koslow M. Hiesiger E.M. Hymes K.B. Hochster H.S. Moore E.J. Pierz D.M. Chen D.K. Budzilovich G.N. Ransohoff J. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma Cancer 76 1995 840 852 10.1002/1097-0142(19950901)76:5<840::aid-cncr2820760519>3.0.co;2-r 8625188

54 Shimizu K. Okamoto Y. Miyao Y. Yamada M. Ushio Y. Hayakawa T. Ikeda H. Mogami H. Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2 J. Neurosurg. 66 1987 519 521 10.3171/jns.1987.66.4.0519 3494108

55 Yoshida S. Takai N. Saito T. Tanaka R. Adoptive immunotherapy in patients with malignant glioma] Gan To Kagaku Ryoho. 14 1987 1930 1932 3496052

56 Merchant R.E. Grant A.J. Merchant L.H. Young H.F. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2 Cancer 62 1988 665 671 10.1002/1097-0142(19880815)62:4<665::aid-cncr2820620403>3.0.co;2-o 2840186

57 Merchant R.E. Merchant L.H. Cook S.H. McVicar D.W. Young H.F. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor Neurosurgery 23 1988 725 732 10.1227/00006123-198812000-00007 2851116

58 Yoshida S. Takai N. Ono K. Saito T. Tanaka R. Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas] No Shinkei 40 1988 119 125 3259433

59 Yoshida S. Tanaka R. Takai N. Ono K. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors Cancer Res. 48 1988 5011 5016 3261631

60 Atkinson L.L. Merchant R.E. Ghatak N.R. Young H.F. Sterile abscesses in glioma patients treated by intraparenchymal injection of lymphokine-activated killer cells and recombinant interleukin-2: case reports Neurosurgery 25 1989 805 810 10.1097/00006123-198911000-00019 2586734

61 Barba D. Saris S.C. Holder C. Rosenberg S.A. Oldfield E.H. Intratumoral LAK cell and interleukin-2 therapy of human gliomas J. Neurosurg. 70 1989 175 182 10.3171/jns.1989.70.2.0175 2643685

62 Naganuma H. Kimurat R. Sasaki A. Fukamachi A. Nukui H. Tasaka K. Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report Acta Neurochir. 99 1989 157 160 10.1007/bf01402326 2549767

63 Shimizu K. Tamura K. Yamada M. Okamoto Y. Miyao Y. Park K. Matsui Y. Hayakawa T. Takimoto H. Mogami H. Adoptive immunotherapy in patients with medulloblastoma by LAK cells] No Shinkei 41 1989 991 995 2605046

64 Munari L. Silvani A. Passerini C.G. Radrizzani M. Parmiani G. Boiardi A. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme J. Neurosurg. Sci. 34 1990 283 288 1965907

65 Nitta T. Ishizawa A. Ito M. Sato K. Yagita H. Kumura K. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells] Noshinkeigeka 18 1990 1001 1006 2247192

66 Nitta T. Sato K. Yagita H. Okumura K. Ishii S. Preliminary trial of specific targeting therapy against malignant glioma Lancet 335 1990 368 371 10.1016/0140-6736(90)90205-j 1968115

67 Lillehei K.O. Mitchell D.H. Johnson S.D. McCleary E.L. Kruse C.A. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy Neurosurgery 28 1991 16 23 10.1097/00006123-199101000-00003 1994273

68 Thomas C. Schober R. Lenard H.G. Lumenta C.B. Jacques D.B. Wechsler W. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma Neuropediatrics 23 1992 123 125 10.1055/s-2008-1071326 1641079

69 Blancher A. Roubinet F. Grancher A.S. Tremoulet M. Bonaté A. Delisle M.B. Calot J.P. Pourreau C. Franks C. Ducos J. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells Eur. Cytokine Netw. 4 1993 331 341 8117934

70 Ibayashi Y. Yamaki T. Kawahara T. Daibo M. Kubota T. Uede T. Tanabe S. Hashi K. Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients Neurol. Med.-Chir. 33 1993 448 457 10.2176/nmc.33.448 7692323

71 Jeffes E.W. 3rd Beamer Y.B. Jacques S. Silberman R.S. Vayuvegula B. Gupta S. Coss J.S. Yamamoto R.S. Granger G.A. Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA J. Neuro Oncol. 15 1993 141 155 10.1007/bf01053935 8509819

72 Nagane M. Oyama H. Shibui S. Nomura K. Recurrence with tumor bleeding in a patient with malignant astrocytoma during the treatment with intracranial injection of lymphokine-activated killer cells--a case report No To Shinkei 45 1993 547 551 8395864

73 Boiardi A. Silvani A. Ruffini P.A. Rivoltini L. Parmiani G. Broggi G. Salmaggi A. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients Cancer Immunol. Immunother. 39 1994 193 197 10.1007/bf01533386 7923250 PMC11038507

74 Nakagawa K. Kamezaki T. Shibata Y. Tsunoda T. Meguro K. Nose T. Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors Neurol. Med.-Chir. 35 1995 22 27 10.2176/nmc.35.22 7700478

75 Sankhla S.K. Nadkarni J.S. Bhagwati S.N. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors J. Neuro Oncol. 27 1996 133 140 10.1007/bf00177476 8699235

76 Naganuma H. Sasaki A. Satoh E. Nagasaka M. Isoe S. Nakano S. Nukui H. Long-term survival in a young patient with anaplastic glioma Brain Tumor Pathol. 14 1997 71 74 10.1007/bf02478872 9384806

77 Hayes R.L. Arbit E. Odaimi M. Pannullo S. Scheff R. Kravchinskiy D. Zaroulis C. Adoptive cellular immunotherapy for the treatment of malignant gliomas Crit. Rev. Oncol. Hematol. 39 2001 31 42 10.1016/s1040-8428(01)00122-6 11418300

78 Huang Y. Hayes R.L. Wertheim S. Arbit E. Scheff R. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report Crit. Rev. Oncol. Hematol. 39 2001 17 23 10.1016/s1040-8428(01)00120-2 11418298

79 Dillman R.O. Duma C.M. Schiltz P.M. DePriest C. Ellis R.A. Okamoto K. Beutel L.D. De Leon C. Chico S. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma J. Immunother. 27 2004 398 404 10.1097/00002371-200409000-00009 15314549

80 Dillman R.O. Duma C.M. Ellis R.A. Cornforth A.N. Schiltz P.M. Sharp S.L. DePriest M.C. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma J. Immunother. 32 2009 914 919 10.1097/CJI.0b013e3181b2910f 19816190

81 Okamoto Y. Shimizu K. Tamura K. Miyao Y. Yamada M. Matsui Y. Tsuda N. Takimoto H. Hayakawa T. Mogami H. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK) Acta Neurochir. 94 1988 47 52 10.1007/bf01406615 3177046

82 Hida T. Koike K. Sekido Y. Nishida K. Sugiura T. Ariyoshi Y. Takahashi T. Ueda R. Epitope analysis of cluster 1 and NK cell-related monoclonal antibodies Br. J. Cancer Suppl. 14 1991 24 28 1710138 PMC2204105

83 Rosenberg S.A. Spiess P. Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 233 1986 1318 1321 10.1126/science.3489291 3489291

84 Smith M.M. Thompson J.E. Castillo M. Cush S. Mukherji S.K. Miller C.H. Quattrocchi K.B. MR of recurrent high-grade astrocytomas after intralesional immunotherapy AJNR. Am. J. Neuroradiol. 17 1996 1065 1071 8791917 PMC8338604

85 Holladay F.P. Heitz-Turner T. Bayer W.L. Wood G.W. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma J. Neuro Oncol. 27 1996 179 189 10.1007/bf00177482 8699241

86 Kruse C.A. Cepeda L. Owens B. Johnson S.D. Stears J. Lillehei K.O. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 Cancer Immunol. Immunother. 45 1997 77 87 10.1007/s002620050405 9390198 PMC11037563

87 Plautz G.E. Barnett G.H. Miller D.W. Cohen B.H. Prayson R.A. Krauss J.C. Luciano M. Kangisser D.B. Shu S. Systemic T cell adoptive immunotherapy of malignant gliomas J. Neurosurg. 89 1998 42 51 10.3171/jns.1998.89.1.0042 9647171

88 Tsurushima H. Liu S.Q. Tuboi K. Matsumura A. Yoshii Y. Nose T. Saijo K. Ohno T. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes Jpn. J. Cancer Res. 90 1999 536 545 10.1111/j.1349-7006.1999.tb00781.x 10391094 PMC5926095

89 Plautz G.E. Miller D.W. Barnett G.H. Stevens G.H. Maffett S. Kim J. Cohen P.A. Shu S. T cell adoptive immunotherapy of newly diagnosed gliomas Clin. Cancer Res. 6 2000 2209 2218 10873070

90 Wood G.W. Holladay F.P. Turner T. Wang Y.Y. Chiga M. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma J. Neuro Oncol. 48 2000 113 120 10.1023/a:1006456421177 11083074

91 Sloan A.E. Dansey R. Zamorano L. Barger G. Hamm C. Diaz F. Baynes R. Wood G. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes Neurosurg. Focus 9 2000 e9 10.3171/foc.2000.9.6.10 16817692

92 Tsuboi K. Saijo K. Ishikawa E. Tsurushima H. Takano S. Morishita Y. Ohno T. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas Clin. Cancer Res. 9 2003 3294 3302 12960115

93 Peres E. Wood G.W. Poulik J. Baynes R. Sood S. Abidi M.H. Klein J. Bhambhani K. Dansey R. Abella E. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors Neuropediatrics 39 2008 151 156 10.1055/s-0028-1093333 18991194

94 Katakura R. Suzuki Y. Sekine T. Sasaki Y.F. Fujimiya Y. Therapeutic Efficacy of Adoptive Cell Transfer on Survival of Patients with Glioblastoma Multiforme: Case Reports Case Rep. Oncol. 3 2010 110 124 10.1159/000313629 20740183 PMC2919986

95 Crough T. Beagley L. Smith C. Jones L. Walker D.G. Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme Immunol. Cell Biol. 90 2012 872 880 10.1038/icb.2012.19 22508289

96 Kanemura Y. Sumida M. Okita Y. Yoshioka E. Yamamoto A. Kanematsu D. Handa Y. Fukusumi H. Inazawa Y. Takada A.I. Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma Anticancer Res. 37 2017 3921 3932 10.21873/anticanres.11775 28668896

97 Kong D.S. Nam D.H. Kang S.H. Lee J.W. Chang J.H. Kim J.H. Lim Y.J. Koh Y.C. Chung Y.G. Kim J.M. Kim C.H. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea Oncotarget 8 2017 7003 7013 10.18632/oncotarget.12273 27690294 PMC5351686

98 Kirkin A.F. Dzhandzhugazyan K.N. Guldberg P. Fang J.J. Andersen R.S. Dahl C. Mortensen J. Lundby T. Wagner A. Law I. Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells Nat. Commun. 9 2018 785 10.1038/s41467-018-03217-9 29511178 PMC5840134

99 Roszman T. Elliott L. Brooks W. Modulation of T-cell function by gliomas Immunol. Today 12 1991 370 374 10.1016/0167-5699(91)90068-5 1958290

100 Zinkernagel R.M. Doherty P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system Nature 248 1974 701 702 10.1038/248701a0 4133807

101 Facoetti A. Nano R. Zelini P. Morbini P. Benericetti E. Ceroni M. Campoli M. Ferrone S. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors Clin. Cancer Res. 11 2005 8304 8311 10.1158/1078-0432.Ccr-04-2588 16322289

102 Khatua S. Cooper L.J.N. Sandberg D.I. Ketonen L. Johnson J.M. Rytting M.E. Liu D.D. Meador H. Trikha P. Nakkula R.J. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma Neuro Oncol. 22 2020 1214 1225 10.1093/neuonc/noaa047 32152626 PMC7594549

103 Lim J. Park Y. Ahn J.W. Sim J. Kang S.J. Hwang S. Chun J. Choi H. Kim S.H. Chun D.H. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial PLoS One 16 2021 e0247293 10.1371/journal.pone.0247293 PMC7946298 33690665

104 Asl N.S. Behfar M. Amiri R.S. Mohseni R. Azimi M. Firouzi J. Faranoush M. Izadpanah A. Mohmmad M. Hamidieh A.A. Intra-lesion injection of activated Natural Killer (NK) cells in recurrent malignant brain tumors Int. Immunopharmacol. 120 2023 110345 10.1016/j.intimp.2023.110345 37267858

105 Burger M.C. Forster M.T. Romanski A. Straßheimer F. Macas J. Zeiner P.S. Steidl E. Herkt S. Weber K.J. Schupp J. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma Neuro Oncol. 25 2023 2058 2071 10.1093/neuonc/noad087 37148198 PMC10628939

106 Mahdizadeh H. Izadpanah A. Nouri Y. Shams P. Daneshjou D. Ahari A.A. Tabibkhooei A. Haghighatkhah H. Vosough M. Faranoush P. The safety and feasibility of multiple intrathecal injections of allogenic NK cells in pediatrics with refractory/recurrent brain tumors BMC Cancer 25 2025 952 10.1186/s12885-025-14314-6 40426086 PMC12117714

107 Carlsten M. Childs R.W. Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications Front. Immunol. 6 2015 266 10.3389/fimmu.2015.00266 26113846 PMC4462109

108 Eshhar Z. Waks T. Gross G. Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors Proc. Natl. Acad. Sci. USA 90 1993 720 724 10.1073/pnas.90.2.720 8421711 PMC45737

109 Brocker T. Peter A. Traunecker A. Karjalainen K. New simplified molecular design for functional T cell receptor Eur. J. Immunol. 23 1993 1435 1439 10.1002/eji.1830230705 8325320

110 Yarmarkovich M. Marshall Q.F. Warrington J.M. Premaratne R. Farrel A. Groff D. Li W. di Marco M. Runbeck E. Truong H. Targeting of intracellular oncoproteins with peptide-centric CARs Nature 623 2023 820 827 10.1038/s41586-023-06706-0 37938771 PMC10665195

111 Fielding A.K. Richards S.M. Chopra R. Lazarus H.M. Litzow M.R. Buck G. Durrant I.J. Luger S.M. Marks D.I. Franklin I.M. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study Blood 109 2007 944 950 10.1182/blood-2006-05-018192 17032921

112 Vitanza N.A. Ronsley R. Choe M. Seidel K. Huang W. Rawlings-Rhea S.D. Beam M. Steinmetzer L. Wilson A.L. Brown C. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial Nat. Med. 31 2025 861 868 10.1038/s41591-024-03451-3 39775044 PMC11922736

113 Del Bufalo F. De Angelis B. Caruana I. Del Baldo G. De Ioris M.A. Serra A. Mastronuzzi A. Cefalo M.G. Pagliara D. Amicucci M. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma N. Engl. J. Med. 388 2023 1284 1295 10.1056/NEJMoa2210859 37018492

114 Ventin M. Cattaneo G. Maggs L. Arya S. Wang X. Ferrone C.R. Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy: A Review JAMA Oncol. 10 2024 115 121 10.1001/jamaoncol.2023.4504 37943567

115 Timpanaro A. Song E.Z. Amwas N. Chiu C.H. Ronsley R. Taylor M.R. Foster J.B. Wang L.D. Vitanza N.A. Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors Cancer Discov. 15 2025 890 902 10.1158/2159-8290.Cd-24-1465 40300089 PMC12048232

116 Burns I. Gwynne W.D. Suk Y. Custers S. Chaudhry I. Venugopal C. Singh S.K. The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues Front. Oncol. 12 2022 815726 10.3389/fonc.2022.815726 PMC8829546 35155252

117 Haydar D. Ibañez-Vega J. Krenciute G. T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges Front. Oncol. 11 2021 718030 10.3389/fonc.2021.718030 PMC8573171 34760690

118 Park S. Maus M.V. Choi B.D. CAR-T cell therapy for the treatment of adult high-grade gliomas npj Precis. Oncol. 8 2024 279 10.1038/s41698-024-00753-0 39702579 PMC11659528

119 Ronsley R. Bertrand K.C. Song E.Z. Timpanaro A. Choe M. Tlais D. Vitanza N.A. Park J.R. CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials Cancer Metastasis Rev. 43 2024 1205 1216 10.1007/s10555-024-10208-4 39251462 PMC11554695

120 Yaacoub S. Vannoy E. Maslova S. Haffey A. Khorsandi K. Sheybani N. Haydar D. CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence Front. Immunol. 16 2025 1596499 10.3389/fimmu.2025.1596499 PMC12222291 40612954

121 Begley S.L. O'Rourke D.M. Binder Z.A. CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials Mol. Ther. 33 2025 2454 2461 10.1016/j.ymthe.2025.03.004 40057825 PMC12172181

122 Zhou D. Zhu X. Xiao Y. Advances in CAR-T therapy for central nervous system tumors Biomark. Res. 12 2024 132 10.1186/s40364-024-00679-6 39506843 PMC11539471

123 Binder Z.A. Bagley S.J. Foster J.B. O'Rourke D.M. The development of CAR T cells for patients with CNS malignancies Nat. Rev. Clin. Oncol. 23 2026 137 150 10.1038/s41571-025-01102-1 41326789 PMC12854404

124 Grewal E.P. Nahed B.V. Carter B.S. Gerstner E.R. Curry W.T. Maus M.V. Choi B.D. Clinical progress in the development of CAR T cells to treat malignant glioma J. Neuro Oncol. 171 2025 571 579 10.1007/s11060-024-04909-7 39695004

125 Królikowska A. Tarnowski M. CAR-T cells immunotherapy in the treatment of glioblastoma Cancer Immunol. Immunother. 74 2025 363 10.1007/s00262-025-04222-w 41196398 PMC12592620

126 Sabahi M. Fathi Jouzdani A. Sadeghian Z. Dabbagh Ohadi M.A. Sultan H. Salehipour A. Maniakhina L. Rezaei N. Adada B. Mansouri A. Borghei-Razavi H. CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws J. Neuro Oncol. 171 2025 495 530 10.1007/s11060-024-04876-z 39538038

127 Monje M. Mahdi J. Majzner R. Yeom K.W. Schultz L.M. Richards R.M. Barsan V. Song K.W. Kamens J. Baggott C. Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas Nature 637 2025 708 715 10.1038/s41586-024-08171-9 39537919 PMC11735388

128 Keu K.V. Witney T.H. Yaghoubi S. Rosenberg J. Kurien A. Magnusson R. Williams J. Habte F. Wagner J.R. Forman S. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma Sci. Transl. Med. 9 2017 eaag2196 10.1126/scitranslmed.aag2196 PMC5260938 28100832

129 Brown C.E. Rodriguez A. Palmer J. Ostberg J.R. Naranjo A. Wagner J.R. Aguilar B. Starr R. Weng L. Synold T.W. Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma Neuro Oncol. 24 2022 1318 1330 10.1093/neuonc/noac024 35100373 PMC9340633

130 Vitanza N.A. Wilson A.L. Huang W. Seidel K. Brown C. Gustafson J.A. Yokoyama J.K. Johnson A.J. Baxter B.A. Koning R.W. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety Cancer Discov. 13 2023 114 131 10.1158/2159-8290.CD-22-0750 36259971 PMC9827115

131 Tang X. Wang Y. Huang J. Zhang Z. Liu F. Xu J. Guo G. Wang W. Tong A. Zhou L. Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma Signal Transduct. Target. Ther. 6 2021 125 10.1038/s41392-021-00505-7 33767145 PMC7994554

132 Gust J. Cole B.L. Ronsley R. Wilson A.L. Seidel K. Wendler J. Pattabhi S. Brown C. Rawlings-Rhea S.D. Shtanukhina N. Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial Neuro Oncol. 27 2025 2170 2181 10.1093/neuonc/noaf064 40070357 PMC12448881

133 O'Rourke D.M. Nasrallah M.P. Desai A. Melenhorst J.J. Mansfield K. Morrissette J.J.D. Martinez-Lage M. Brem S. Maloney E. Shen A. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma Sci. Transl. Med. 9 2017 eaaa0984 10.1126/scitranslmed.aaa0984 28724573 PMC5762203

134 Durgin J.S. Henderson F. Jr. Nasrallah M.P. Mohan S. Wang S. Lacey S.F. Melenhorst J.J. Desai A.S. Lee J.Y.K. Maus M.V. Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma Front. Oncol. 11 2021 669071 10.3389/fonc.2021.669071 PMC8138201 34026647

135 Goff S.L. Morgan R.A. Yang J.C. Sherry R.M. Robbins P.F. Restifo N.P. Feldman S.A. Lu Y.C. Lu L. Zheng Z. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma J. Immunother. 42 2019 126 135 10.1097/cji.0000000000000260 30882547 PMC6691897

136 Bagley S.J. Binder Z.A. Lamrani L. Marinari E. Desai A.S. Nasrallah M.P. Maloney E. Brem S. Lustig R.A. Kurtz G. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial Nat. Cancer 5 2024 517 531 10.1038/s43018-023-00709-6 38216766

137 Lin Q. Ba T. Ho J. Chen D. Cheng Y. Wang L. Xu G. Xu L. Zhou Y. Wei Y. First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose Front. Oncol. 11 2021 694941 10.3389/fonc.2021.694941 PMC8256846 34235085

138 Liu Z. Zhou J. Yang X. Liu Y. Zou C. Lv W. Chen C. Cheng K.K.Y. Chen T. Chang L.J. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma Mol. Cancer 22 2023 3 10.1186/s12943-022-01711-9 PMC9827625 36617554

139 Vitanza N.A. Johnson A.J. Wilson A.L. Brown C. Yokoyama J.K. Künkele A. Chang C.A. Rawlings-Rhea S. Huang W. Seidel K. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis Nat. Med. 27 2021 1544 1552 10.1038/s41591-021-01404-8 34253928

140 Brown C.E. Hibbard J.C. Alizadeh D. Blanchard M.S. Natri H.M. Wang D. Ostberg J.R. Aguilar B. Wagner J.R. Paul J.A. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial Nat. Med. 30 2024 1001 1012 10.1038/s41591-024-02875-1 38454126 PMC11031404

141 Barish M.E. Aftabizadeh M. Hibbard J. Blanchard M.S. Ostberg J.R. Wagner J.R. Manchanda M. Paul J. Stiller T. Aguilar B. Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety Cell Rep. Med. 6 2025 102302 10.1016/j.xcrm.2025.102302 PMC12432350 40818458

142 Bagley S.J. Desai A.S. Fraietta J.A. Silverbush D. Chafamo D. Freeburg N.F. Gopikrishna G.K. Rech A.J. Nabavizadeh A. Bagley L.J. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial Nat. Med. 31 2025 2778 2787 10.1038/s41591-025-03745-0 40451950 PMC12715680

143 Brown C.E. Aguilar B. Starr R. Yang X. Chang W.C. Weng L. Chang B. Sarkissian A. Brito A. Sanchez J.F. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma Mol. Ther. 26 2018 31 44 10.1016/j.ymthe.2017.10.002 29103912 PMC5763077

144 Mahdi J. Dietrich J. Straathof K. Roddie C. Scott B.J. Davidson T.B. Prolo L.M. Batchelor T.T. Campen C.J. Davis K.L. Tumor inflammation-associated neurotoxicity Nat. Med. 29 2023 803 810 10.1038/s41591-023-02276-w 37024595 PMC10166099

145 Macdonald D.R. Cascino T.L. Schold S.C. Jr. Cairncross J.G. Response criteria for phase II studies of supratentorial malignant glioma J. Clin. Oncol. 8 1990 1277 1280 10.1200/jco.1990.8.7.1277 2358840

146 Brandsma D. Stalpers L. Taal W. Sminia P. van den Bent M.J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol. 9 2008 453 461 10.1016/s1470-2045(08)70125-6 18452856

147 Wen P.Y. Macdonald D.R. Reardon D.A. Cloughesy T.F. Sorensen A.G. Galanis E. Degroot J. Wick W. Gilbert M.R. Lassman A.B. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J. Clin. Oncol. 28 2010 1963 1972 10.1200/jco.2009.26.3541 20231676

148 Wen P.Y. van den Bent M. Youssef G. Cloughesy T.F. Ellingson B.M. Weller M. Galanis E. Barboriak D.P. de Groot J. Gilbert M.R. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults J. Clin. Oncol. 41 2023 5187 5199 10.1200/jco.23.01059 37774317 PMC10860967

149 Brummer A.B. Yang X. Ma E. Gutova M. Brown C.E. Rockne R.C. Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy PLoS Comput. Biol. 18 2022 e1009504 10.1371/journal.pcbi.1009504 PMC8820647 35081104

Supplemental information

Document S1. Tables S1 and S2 Document S2. Article plus supplemental information

Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2026.102626 .